MMR immunization could offer assurance against COVID-19 Kumar Jeetendra | June 20, 2020 Directing the MMR (measles, mumps, rubella) antibody could fill in as a preventive measure to hose septic aggravation related with COVID-19 disease, state a group of specialists in the current week’s mBio, a diary of the American Society for Microbiology. Long-term colleagues and life partners Dr. Paul Fidel, Jr., Department Chair, Oral and Craniofacial Biology, …
Asthma doesn’t seem to expand the danger of contracting COVID-19, shows study Kumar Jeetendra | July 6, 2020 Asthma doesn’t seem to increase the risk for an individual contracting COVID-19 or influence its own seriousness, as shown by a group of Rutgers research workers. “However, individuals with allergies –even those with diminished lung function that are being treated to control asthmatic inflammation–appear like no worse influenced by SARS-CoV-2 compared to the usual non-asthmatic …
Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals Kumar Jeetendra | July 25, 2020 Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. MRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune …
Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups Kumar Jeetendra | August 1, 2020 HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated …
Protein delivered by the human safe framework can emphatically hinder Sars-Cov-2 Kumar Jeetendra | August 3, 2020 A protein produced by the human immune system may strongly inhibit corona viruses, including Sars-Cov-2, the pathogen causing Covid-19. An international team from Germany, Switzerland and the USA successfully showed the LY6E-Protein prevents coronaviruses from causing the illness. “This finding may result in the development of new therapeutic approaches against coronaviruses,” says Professor Stephanie Pfänder …
Propelled investigation offers new experiences into safe framework’s job in serious COVID-19 Kumar Jeetendra | August 14, 2020 By conducting complex diagnoses of immune system stimulation in patients with acute COVID-19, researchers at Karolinska Institutet have managed to spot several cell types that play a key part in the immune reaction to the new coronavirus and the hyperinflammation found in severe cases of the disease. The results are published in the scientific journal …
New T-cell-based immunization procedure gives more extensive insurance against occasional flu Kumar Jeetendra | September 24, 2020 As Americans begin pulling their sleeves up for an annual flu vaccine, researchers at the University of Wisconsin-Madison have provided new insights into an alternate vaccine approach that provides wider protection against seasonal flu. In a study published in Cell Reports Medicine today (Sept. 22), scientists describe a T-cell-based vaccine strategy that’s effective against multiple …
PC model disentangles puzzle behind serious aggravation in individuals with COVID-19 Kumar Jeetendra | September 29, 2020 A study from the University of Pittsburgh School of Medicine and Cedars-Sinai addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation? The research shows how the molecular arrangement and arrangement of the SARS-CoV-2 spike protein–part of the virus that causes COVID-19–could be behind the inflammatory syndrome cropping up …
New initiative identifies key parameters Inherent effective anti-tumor immunity Kumar Jeetendra | October 10, 2020 Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies. Targeting the”right” neoantigens – at a cancer vaccine or a cell treatment – has the promise to eliminate a patient’s cancer with minimal side effects. But countless mutations can exist in …
Study gives conceivable clarification to reformist course of different sclerosis in mice Kumar Jeetendra | October 17, 2020 People with multiple sclerosis (MS) gradually develop increasing functional impairment. Researchers at Karolinska Institutet in Sweden have found a possible explanation for the progressive course of this disease in mice and how it can be reversed. The analysis, which is published in Science Immunology, can prove beneficial to future treatments. MS is a chronic inflammatory …
Drug used to control pulse may improve malignant growth patients’ reaction to immunotherapy Kumar Jeetendra | November 1, 2020 The exact same biochemical triggers which spur a”flight or fight” reaction once we encounter threats may help tumor cells to thrive. A group of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to interrupt that dynamic so that cancer therapies can be effective. Their latest work, published today in Clinical Cancer Research, …
Blood vessel deformities start in vein cells Kumar Jeetendra | November 3, 2020 In the condition called cavernoma, lesions appear in a cluster of blood vessels in the brain, spinal cord or retina. Researchers from Uppsala University can now reveal, at molecular level, these changes originate in vein cells. This new understanding of the condition creates possibility of developing better treatments for patients. The study was published in …
